Acetylsalicylic acid for venous thromboembolism prophylaxis: a review of clinical evidence, benefits and harms
Canadian Agency for Drugs and Technologies in Health
Record ID 32011001509
English
Authors' recommendations:
Most of the available evidence from two studies suggested that ASA results in fewer surgical site bleeds and is as effective as vitamin K agonists, low molecular weight heparin, or pentasaccharides for preventing venous thromboembolism after total hip arthroplasty, total knee arthroplasty, and hip fracture surgery. A prospective cohort study suggested that acetylsalicylic acid is less efficacious than low molecular weight heparin in reducing the risk of venous thromboembolism in standard-risk patients
Details
Project Status:
Completed
Year Published:
2011
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Primary Prevention
- Venous Thromboembolism
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.